Literature DB >> 26025425

Presbyopic LASIK using hybrid bi-aspheric micro-monovision ablation profile for presbyopic corneal treatments.

Michiel H A Luger1, Colm McAlinden2, Philip J Buckhurst3, James S Wolffsohn4, Shwetabh Verma5, Samuel Arba Mosquera5.   

Abstract

PURPOSE: To evaluate distance and near image quality after hybrid bi-aspheric multifocal central presbyLASIK treatments.
DESIGN: Consecutive case series.
METHODS: Sixty-four eyes of 32 patients consecutively treated with central presbyLASIK were assessed. The mean age of the patients was 51 ± 3 years with a mean spherical equivalent refraction of -1.08 ± 2.62 diopters (D) and mean astigmatism of 0.52 ± 0.42 D. Monocular corrected distance visual acuity (CDVA), corrected near visual acuity (CNVA), and distance corrected near visual acuity (DCNVA) of nondominant eyes; binocular uncorrected distance visual acuity (UDVA); uncorrected intermediate visual acuity (UIVA); distance corrected intermediate visual acuity (DCIVA); and uncorrected near visual acuity (UNVA) were assessed pre- and postoperatively. Subjective quality of vision and near vision was assessed using the 10-item Rasch-scaled Quality of Vision and Near Activity Visual Questionnaire, respectively.
RESULTS: At 1 year postoperatively, 93% of patients achieved 20/20 or better binocular UDVA; 90% and 97% of patients had J2 or better UNVA and UIVA, respectively; 7% lost 2 Snellen lines of CDVA; Strehl ratio reduced by ∼-4% ± 14%. Defocus curves revealed a loss of half a Snellen line at best focus, with no change for intermediate vergence (-1.25 D) and a mean gain of 2 lines for near vergence (-3 D).
CONCLUSIONS: Presbyopic treatment using a hybrid bi-aspheric micro-monovision ablation profile is safe and efficacious. The postoperative outcomes indicate improvements in binocular vision at far, intermediate, and near distances with improved contrast sensitivity. A 19% retreatment rate should be considered to increase satisfaction levels, besides a 3% reversal rate.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26025425     DOI: 10.1016/j.ajo.2015.05.021

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

1.  One year results of presbyLASIK using hybrid bi-aspheric micro-monovision ablation profile in correction of presbyopia and myopic astigmatism.

Authors:  Fang Liu; Ting Zhang; Quan Liu
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

Review 2.  Refractive surgery beyond 2020.

Authors:  Marcus Ang; Damien Gatinel; Dan Z Reinstein; Erik Mertens; Jorge L Alió Del Barrio; Jorge L Alió
Journal:  Eye (Lond)       Date:  2020-07-24       Impact factor: 3.775

Review 3.  Corneal compensation of presbyopia: PresbyLASIK: an updated review.

Authors:  Veronica Vargas-Fragoso; Jorge L Alió
Journal:  Eye Vis (Lond)       Date:  2017-04-13

4.  Comparison of a hydrogel corneal inlay and monovision laser in situ keratomileusis in presbyopic patients: focus on visual performance and optical quality.

Authors:  Cornelis Verdoorn
Journal:  Clin Ophthalmol       Date:  2017-09-20

5.  Comparing Patient-Reported Outcomes of Laser In Situ Keratomileusis and Small-Incision Lenticule Extraction: A Review.

Authors:  Nathalie P Y Chiam; Jodhbir S Mehta
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2019 Sep-Oct

6.  One Year Outcome and Satisfaction of Presbyopia Correction Using the PresbyMAX® Monocular Ablation Profile.

Authors:  Dan Fu; Jing Zhao; Li Zeng; Xingtao Zhou
Journal:  Front Med (Lausanne)       Date:  2020-11-27

Review 7.  PresbyLASIK: A review of PresbyMAX, Supracor, and laser blended vision: Principles, planning, and outcomes.

Authors:  Rohit Shetty; Sheetal Brar; Mohita Sharma; Zelda Dadachanji; Vaitheeswaran Ganesan Lalgudi
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

Review 8.  Correction of presbyopia: An integrated update for the practical surgeon.

Authors:  Marie Joan Therese D Balgos; Veronica Vargas; Jorge L Alió
Journal:  Taiwan J Ophthalmol       Date:  2018 Jul-Sep
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.